NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SNTI
Senti Biosciences, Inc.
There isn't enough reported data to score SNTI yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SNTI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
SNTI's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SNTI PE Valuation
SNTI has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SNTI Forward outlook
There aren't enough analyst estimates for SNTI to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over SNTI in the latest year-over-year earnings comparison.
SNTI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$27.34 | -$6.04 |
| Q2 2024 | -$24.43 | -$2.73 |
| Q1 2024 | -$26.18 | -$0.08 |
SNTI is still losing money, but far less than before: $1.79 per share over the past year, against $27.78 at its worst in late 2023.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SNTI on profitability, with a higher operating margin.
SNTI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2023 | $338K | -81% |
| Q2 2023 | $937K | -31% |
| Q4 2022 | $59K | -93% |
| Q4 2021 | $793K | +39550% |
SNTI's revenue has slid since its 2022 peak: $17,000 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -85229% | N/A |
| Q1 2026 | -28850% | N/A |
| Q3 2023 | -12981% | -12014 points |
| Q2 2023 | -2096% | -492 points |
| Q1 2023 | -1542% | N/A |
| Q4 2022 | -33925% | -32553 points |
| Q3 2022 | -967% | N/A |
| Q2 2022 | -1603% | N/A |
SNTI's operating margin was −85229% last quarter, down 83687 points from the same quarter a year ago, near the bottom of its range since 2020.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over SNTI on cash generation, producing positive trailing cash flow while its opponent burns cash.
SNTI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$7.5M | +$6.6M |
| Q4 2025 | -$6.9M | +$6.6M |
| Q3 2025 | -$9.4M | -$1.6M |
| Q2 2025 | -$13.3M | -$4.9M |
| Q1 2025 | -$14.1M | -$2.4M |
| Q4 2024 | -$13.5M | -$6.5M |
| Q3 2024 | -$7.9M | +$9.4M |
| Q2 2024 | -$8.3M | +$9M |
SNTI has burned cash in almost every quarter: −$37M over the past year, against −$44M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over SNTI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SNTI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +173K shares |
| 1 year | +211% | +21.1M shares |
| 3 years | +607% | +26.7M shares |
SNTI has 31M diluted shares, up 211% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
SNTI Net Leverage
SNTI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SNTI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.7 | Oversold |
| Stochastic | 3.2 | Oversold |
SNTI's weekly RSI is 25 (oversold) and its Stochastic is 3 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SNTI PE vs Healthcare Sector
SNTI has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over SNTI on trend strength, trading above more of its moving averages.
SNTI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.23 | 35% below |
| 20 week MA | $0.38 | 61% below |
| 50 week MA | $0.77 | 81% below |
| 100 week MA | $1.79 | 92% below |
| 200 week MA | $3.87 | 96% below |
SNTI is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over SNTI on returns for 2026, with the stronger performance.
SNTI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $100.0 | $98.5 | -1.5% |
| 2022 | $98.5 | $13.4 | -86% |
| 2023 | $13.4 | $6.60 | -51% |
| 2024 | $6.60 | $3.92 | -41% |
| 2025 | $3.92 | $1.06 | -73% |
| 2026 YTD | $1.06 | $0.15 | -86% |
SNTI has finished every year since 2021 lower, and it's down 86% so far in 2026.